FDA declares semaglutide injection shortage resolved (February 2025)
Wegovy / Ozempic (semaglutide) · Announced 2025-02-21 · Last reviewed July 2026
On February 21, 2025 the FDA announced its determination that the shortage of semaglutide injection products (Wegovy and Ozempic) was resolved, with Novo Nordisk able to meet current and projected US demand. Because compounding of "essentially a copy" of an FDA-approved drug is only permitted during a shortage, the determination started a wind-down period for compounded semaglutide: 503A compounding pharmacies were given until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop producing it. Telehealth services that had offered compounded semaglutide during the shortage transitioned patients to branded Wegovy/Ozempic or alternative therapies.
What's affected
- All semaglutide injection products (Wegovy, Ozempic) — off the FDA shortage list
- Compounded semaglutide from 503A pharmacies (wind-down by April 22, 2025) and 503B facilities (by May 22, 2025)
What patients should do
- If you are still being offered compounded semaglutide, ask the provider what legal basis applies now that the shortage is resolved
- Ask your prescriber about branded options, including Novo's NovoCare self-pay pricing for Wegovy
- If a prior authorization was denied during the shortage era, ask your prescriber whether to resubmit under normalized supply